Loading
A phase 1/2 trial of Oregovomab, Bevacizumab, Paclitaxel / nab-paclitaxel in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT04938583 by CanariaBio Inc., with 54 participants planned, started 2021-03-17 and due to reach its primary completion in 2025-10-30. Interventions recorded: Oregovomab, Bevacizumab, Paclitaxel, Carboplatin. Conditions listed: Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CanariaBio, Oregovomab, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares CanariaBio, Oregovomab, Platinum-sensitive ovarian cancer, Ovarian cancer.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, Paclitaxel / nab-paclitaxel, Platinum agents, Carboplatin.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Platinum-sensitive ovarian cancer, Platinum agents, Carboplatin, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/